Tenosynovial and Transverse Carpal Ligament Biopsy for Early Transthyretin Amyloidosis Cardiomyopathy Detection: A Systematic Review and African American Retrospective Cohort Study Authors: Shireen Dogar, Punn Punnakanta, Marcus D Williams, Youssef al Hamda, Somjade Songcharoen, Mark A Dodson, Marc E Walker Published: 2026 ABSTRACT AbstractPurposePerforming tenosynovial biopsy during carpal tunnel release (CTR) has emerged as a promising diagnostic tool for systemic transthyretin amyloidosis cardiomyopathy (ATTR-CM). Early detection is critical because therapies, such as Tafamidis, have been shown to significantly improve outcomes when initiated prior to heart failure. The Val122Ile mutation (V122I) of the transthyretin (TTR) gene causes hereditary ATTR amyloidosis (hATTR), is found almost exclusively in people of African descent, and is underdiagnosed. The importance of diagnostic feasibility of transverse carpal ligament (TCL) biopsy is critical in the African American population, who often have poorer outcomes from delayed treatment.MethodsWe reviewed 22 studies published between 2017 and 2025 and conducted a retrospective cohort study of patients who underwent CTR at our institution between 2021 and 2025. Intraoperative TCL or A1 pulley specimens were routinely biopsied. All samples were analyzed for the presence of amyloid using Congo Red staining. Demographic data were extracted from the medical record.ResultsOur literature review found that 10% to 30% of CTR specimens contained amyloid deposits, mass spectrometry was the superior analytic modality, and biopsying the TCL in high-risk patients had greater diagnostic yield. At our institution, 89 patients (61.8% African American and 38.2% Caucasian) underwent CTR with concurrent tenosynovial biopsy between 2021 and 2025. The mean age was 55.36 ± 12 years and 32.6% were men. All specimens were analyzed with Congo Red staining. Amyloid deposits were not identified in any specimens.ConclusionsOur negative findings with the largest studied African American population to date underscore the importance of further investigation to refine selection criteria, standardize sampling, and clarify the role of TCL biopsy in early detection of ATTR-CM.Type of study/level of evidenceTherapeutic III.Key words: Amyloidosis, Biopsy, Carpal tunnel release, Carpal tunnel syndrome, Diagnosis, Transthyretin cardiac amyloidosis Transthyretin cardiac amyloidosis (ATTR-CM) is an underdiagnosed, infiltrative cardiomyopathy that disproportionately affects African American patients, particularly those harboring the V122I transthyretin (TTR) mutation.1, 2, 3, 4, 5 Patients with ATTR-CM often present with heart failure with preserved ejection fraction, conduction abnormalities, or arrhythmias; however, the diagnosis is frequently delayed because of nonspecific clinical manifestations and under-recognition in high-risk populations.1,4,6 The V122I mutation that is particularly prevalent in African American patients expresses an allele frequency of approximately 3% to 4% in large cohort studies.3,4 V122I carriers are at increased risk of developing late-onset ATTR-CM.3,4 Despite this strong genetic predisposition, the disease is underdiagnosed, leading to worse clinical outcomes for African Americans. Carpal tunnel syndrome (CTS) is a common early manifestation of ATTR amyloid deposition, and tenosynovial tissue obtained during carpal tunnel release (CTR) has been proposed as a potential site for early detection of amyloid.7, 8, 9, 10, 11 Although multiple studies have evaluated the prevalence of amyloid in CTR specimens, most cohorts examine a predominantly Caucasian population with limited data regarding biopsy yield in African American populations.1,7,10,11 This review’s objective was to examine a larger population of African American participants, given the high prevalence of the V122I allele and risk of ATTR-CM. This review hopes to address the need for refined intervention strategies and focused screening for this population.3, 4, 5, 6 Materials and Methods Peer-reviewed journal articles pertaining to cardiac amyloidosis and carpal tunnel biopsies as a diagnostic tool were identified using PubMed, ScienceDirect, Google Scholar, and CENTRAL. Studies were included for review based on their descriptions of tenosynovial biopsy results for amyloid detection, biopsy technique, consensus guidelines for transverse carpal ligament (TCL) biopsy, efficacy and impact of therapy trials for treatment of cardiac amyloidosis, and genetic mutation trends of cardiac amyloidosis reported for different races, with particular attention to the Black population. Isolated case reports without diagnostic workflow relevance and nonhuman basic science papers were excluded from our review. A total of 22 papers were selected for literature review. These sources were last searched and consulted independently in October 2025 by one author. Coauthors then assessed risk of bias in the included studies based on population size and study design. Authors adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We then performed our own institutional retrospective cohort study to gather more data about the African American population. A total of 89 patients underwent CTR with concurrent TCL and/or tenosynovial biopsy between 2021 and 2025. The mean age was 55.36 ± 12 years, and 32.2% were men. The cohort included 61.1% African American patients and 37.8% Caucasian patients. All specimens were analyzed with Congo Red staining. Amyloid deposits were not identified in any specimens. No biopsy-related complications were recorded. We extracted demographic and clinical data, including gender, age, ethnicity, medical comorbidities (eg, hypertension, coronary artery disease, hyperlipidemia, diabetes, rheumatoid arthritis, and lupus), smoking history, body mass index, bilateral symptoms, prior history of hand surgery, and vital signs on day of surgery, from the electronic medical record. Primary outcomes were the presence of amyloid in TCL and/or tenosynovial specimens, with a focus on African American patients. Secondary outcomes were correlations with age, bilateral CTS, and cardiac comorbidities. Results Our review demonstrated a variable prevalence of amyloid deposition in CTR specimens, ranging from 0% to approximately 10%, with higher detection rates reported in older patients and those with established cardiac amyloidosis.1,7, 8, 9,12, 13, 14, 15 Biopsy techniques included tenosynovial tissue alone, TCL, or both, with studies suggesting that combined sampling may increase diagnostic yield.8,16 Multiple studies evaluated biopsy techniques, including tenosynovial tissue alone, TCL alone, and combined sampling, to optimize amyloid detection rates.3, 4, 5, 6 Ozdag et al3 directly compared tenosynovial versus TCL biopsy in open CTR cases and found that tenosynovial biopsy was superior in terms of amyloid detection sensitivity. They attributed this finding to the fact that amyloid preferentially deposited in tendon sheath rather than the TCL. Their findings also suggested that combined sampling of both sites may increase sensitivity while minimizing complication risk.3 Ferrin et al4 supported this in their meta-analysis, finding that tenosynovium was the most reliable CTR specimen for amyloid screening because ligament tissue alone was not consistently positive across studies. This paper also emphasized that standardizing tissue handling, staining protocols (eg, Congo Red), and histopathological review was critical to ensure reproducibility and diagnostic accuracy.7 Our review also showed that the type of amyloid in CTR specimens varied across studies, depending on patient age, comorbidities, and study cohort composition.6, 7, 8, 9 DiBenedetto et al6 reported that amyloid subtypes in tenosynovial tissue were predominantly wild-type TTR. Additionally, hereditary variants such as V122I were detected in at-risk populations.6 The majority of the literature we reviewed did champion CTS, particularly bilateral or recurrent cases, as a sentinel manifestation of systemic amyloidosis and confirmed that overall yield remained modest.2,4, 5, 6, 7 However, most studies underrepresented African Americans, providing limited conclusions about population-specific screening.4, 5, 6, 7, 8 Several studies attempted to create formal screening strategies. For instance, Zhang et al2 developed an amyloidosis risk score that incorporated sex, age, bilateral disease, and cardiac comorbidities. Ferrin et al3 concluded that routine biopsy for all CTR patients was not warranted and instead championed targeted screening for high-risk patients. At the policy level, the 2023 European Society of Cardiology cardiomyopathy guidelines emphasized the importance of identifying extracardiac “red flag” signs, such as CTS, to trigger further evaluation of amyloidosis.4 Finally, Alsaadi et al14 underscored the urgency of incorporating biopsy into screening pathways for patients with bilateral CTS at higher risk of ATTR-CM. Guidelines now recommend a multimodal approach to early detection, combining clinical evaluation, biomarkers, cardiac imaging, and targeted biopsy in patients deemed high-risk per stratification tools.7,9 Collectively, studies advocated for risk-adapted approaches rather than universal biopsy, which is particularly relevant for our predominantly African American cohort whose biopsy specimens did not show amyloid despite the population’s recognized genetic susceptibility. Because the majority of previous biopsy cohorts had an underrepresentation of African American participants, we performed our own retrospective observational cohort study.5,11,17,18 This cohort, comprising the largest African American population studied to date for tenosynovial and TCL biopsies, demonstrated that all specimens were negative for amyloid deposition. Patient demographics and comorbidities are summarized in Tables 1 and 2. Table 1Study Population Demographics (Gender, Age, Ethnicity, and BMI)GenderMaleCount29Column N %32.6%FemaleCount60Column N %67.4%Age, yMean55Maximum82Minimum18Range64Standard deviation12EthnicityCaucasianCount34Column N %38.2%African AmericanCount55Column N %61.8%BMI, kg/m2Mean32.65Minimum14.80Maximum53.37Range38.57Standard deviation7.44BMI, Body mass index. Study Population Demographics (Gender, Age, Ethnicity, and BMI) BMI, Body mass index. Table 2Study Population ComorbiditiesDiagnosedCountColumn N (%)HypertensionYes5561.8%No3438.2%HyperlipidemiaYes2831.5%No6168.5%Coronary arterial diseaseYes77.9%No8292.1%Diabetes mellitusYes1921.3%No7078.7%Rheumatoid arthritisYes55.6%No8494.4%Systemic lupus erythematosusYes11.1%No8898.9%SmokingYes2123.6%No6876.4% Study Population Comorbidities From all 129 specimens gathered, no specimens were negative for amyloid, including specimens from both Caucasian patients (n = 34) and African American patients (n = 55), summarized in Table 3. Regarding the biopsy specimens, 88 were sampled from the TCL, whereas 41 were sampled from tenosynovium. Interestingly, the African American participants in our study had a high prevalence of medical comorbidities, including hypertension (61.8%), hyperlipidemia (31.5%), diabetes mellitus (21.3%), and other cardiovascular risk factors, which would have placed them into higher risk stratification categories. However, no biopsy specimens were found to contain amyloid. Table 3Amyloid Status of Patients Based on EthnicityVariableEthnicityPathology ReviewPathology ReportCountColumn N %EthnicityCaucasianAmyloidosis statusPositive00.0%Negative34100.0%African AmericanAmyloidosis statusPositive00.0%Negative55100.0% Amyloid Status of Patients Based on Ethnicity Discussion Our findings contrast with current literature reporting a variably positive range of amyloid in CTR specimens, highlighting potential differences in amyloid deposition patterns.1,7,8,12 We know, based on the Ozdag et al3 analysis, that amyloid more consistently deposits in tenosynovial tissue rather than the TCL. Our biopsy specimens were in majority from the TCL, which prior studies state have higher false-negative results. Additionally, studies that included a larger study population of African Americans found that tenosynovial amyloid deposition was less prevalent, suggesting possible differences in tissue tropism (cardiac versus tenosynovium) or even delayed penetrance compared with Caucasian patients.17,19 Although CTR biopsy is feasible and minimally invasive, genetic screening for the V122I mutation, cardiac imaging, and biomarkers may represent equally effective strategies for early detection of ATTR-CM in this higher risk African American population.5,13,14,18 Limitations of our study include its retrospective single-center cohort design, the use of the TCL as the primary sampling site, and the use of Congo Red staining as the method of analysis. Another consideration for our study is that amyloid may not have correlative penetrance in TCL or tenosynovial specimens to fully reflect cardiac amyloid burden.17,19 Future prospective multicenter studies are warranted to determine the diagnostic utility of TCL and tenosynovial biopsy in diverse populations to clarify its role in early detection strategies for ATTR-CM. In conclusion, literature supports the potential of TCL and tenosynovium biopsy during CTR to detect cardiac amyloidosis; however, data for African American populations remain scarce. In our cohort containing the largest sample of African American individuals to date, tenosynovial and TCL biopsy during CTR did not identify amyloid, despite known high genetic risk. Although this does not negate the power of TCL and tenosynovial biopsy as a diagnostic adjunct, it does underscore the need for further population-specific research to improve early detection and management of ATTR-CM. This review was not registered. A review protocol was not prepared. There is no financial support for this review. There are no competing interests of review authors. All data used for our analysis can be accessed in their online journal databases. Conflicts of Interest No benefits in any form have been received or will be received related directly to this article. Acknowledgments The authors gratefully acknowledge support from the American Foundation for Surgery of the Hand (AFSH) through the 2020 Fast Track Clinical Research Grant. References